AstraZeneca, Daiichi Sankyo’s Datroway receives FDA approval for TNBC
AstraZeneca and Daiichi Sankyo have secured approval from the US Food and Drug Administration (FDA) for Datroway (datopotamab deruxtecan) to…
22 May 2026
CVC consortium tables $12.4bn bid to delist Italian drugmaker Recordati
One of Italy’s only publicly traded large pharma companies could soon be taken into private ownership, after private equity firm CVC Capital Partners and Belgian investment group Groupe Bruxelles Lambert…
22 May 2026
European STI cases reach record high amid testing and prevention gaps
New data debuted by the Europe’s infectious disease agency has revealed that cases of certain bacterial sexually transmitted infections (STIs) reached a ten-year high in 2024 as healthcare systems grapple…
22 May 2026
Gilead Sciences completes Tubulis acquisition for $5bn
Gilead Sciences has concluded its acquisition of Tubulis, a Germany-based biotechnology company developing next-generation antibody-drug conjugates (ADCs), in a transaction valued at up to $5bn. First announced last month, the…
22 May 2026
Concept Life Sciences and OpenBench partner on drug discovery services
Concept Life Sciences has signed a strategic partnership with OpenBench to deliver success-based drug discovery services targeted at early-stage biotech companies. The collaboration aims to accelerate hit identification for these…
21 May 2026
Gilead teams up with WHO again to eliminate parasitic tropical disease
Gilead has pledged over 400,000 doses of its antifungal medication to countries affected by a parasitic tropical disease as part of a renewed partnership with the World Health Organization (WHO).…
21 May 2026
Eli Lilly maintains M&A streak with $202m Engage Bio buyout
Pharmaceutical giant Eli Lilly has agreed to acquire Engage Biologics for up to $202m in cash, marking another addition to the company’s growing genetic medicines roster. At the centrepiece of…